Vaginal Dryness: What It Is, Why It Happens, and How to Treat It
By Glow Health | Menopause & Sexual Health Specialists
Vaginal dryness is one of the most common symptoms of the menopausal transition, and one of the least discussed. Many women suffer with it quietly for years, assuming it's simply part of getting older, or feeling too embarrassed to bring it up with a clinician. Others mention it only in passing, not realizing it's a treatable medical condition with effective solutions.
If you're experiencing vaginal dryness, discomfort, irritation, or pain during sex, you are not alone and you don't have to just live with it.
What is vaginal dryness?
Vaginal dryness is a symptom of a broader condition called Genitourinary Syndrome of Menopause (GSM), which encompasses changes to the vulva, vagina, and urinary tract that occur as estrogen levels decline. GSM was previously referred to as vaginal atrophy or atrophic vaginitis, terms that have largely been replaced because they failed to capture the full picture of what women experience.
GSM symptoms include:
Vaginal dryness, irritation, or burning
A sensation of pressure or fullness internally
Pain, discomfort, or tearing during sex
Light bleeding after intercourse
Reduced vaginal lubrication during arousal
Urinary symptoms including urgency, frequency, and recurrent urinary tract infections
Discomfort with everyday activities like exercise or prolonged sitting
Some studies estimate that GSM affects up to 80% of postmenopausal women, yet a survey by The Menopause Society (TMS) found that fewer than 25% of affected women seek treatment. The gap between how common this condition is and how rarely it is treated represents one of the most significant unmet needs in women's health.
Why it happens
Estrogen is essential for maintaining the health of vaginal, vulvar, urethral, and bladder tissue. It keeps the vaginal walls thick, elastic, and well-lubricated, maintains the acidic pH that protects against infection, and supports the integrity of the urethra and bladder. The bladder and urethra are estrogen-dependent tissues just as the vagina is, which is why urinary symptoms, including urgency, frequency, recurrent UTIs, and stress incontinence, are so commonly part of the GSM picture and not a separate, unrelated problem.
As estrogen declines during perimenopause and menopause, vaginal tissue gradually becomes thinner, less elastic, and more fragile. The natural lubrication produced during arousal decreases. The vaginal pH becomes less acidic, increasing susceptibility to bacterial and yeast infections. The urethral tissue thins and becomes more vulnerable to irritation, and the bladder loses some of its protective buffering, contributing to urgency and recurrent infections.
Unlike hot flashes and night sweats, which often improve over time as the body adapts to lower estrogen levels, GSM symptoms tend to persist and worsen without treatment. This makes early intervention particularly valuable.
It's also worth noting that vaginal dryness is not exclusively a postmenopausal problem. Women in perimenopause, women who are breastfeeding, women on certain hormonal contraceptives, and women who have undergone cancer treatment can all experience GSM symptoms due to low estrogen states.
How it affects sexual health and relationships
Vaginal dryness and the pain during sex that often accompanies it can have a profound effect on a woman's sexual health, self-image, and relationships. Pain with intercourse, known clinically as dyspareunia, can lead to:
Avoidance of sexual activity
Decreased libido (often as a learned response to anticipated pain)
Relationship strain and communication difficulties
Anxiety and loss of confidence around intimacy
A sense of grief around changes to an important part of life
These effects are real and deserve to be taken seriously. Sexual health is part of overall health, and clinicians who address vaginal dryness only in terms of physical symptoms without acknowledging its impact on intimacy and quality of life are missing a significant part of the picture.
Treatment options
The good news is that GSM is one of the most treatable conditions associated with menopause. Effective treatment exists for virtually every woman, and the question is not whether you can be treated but which approach is right for you.
Local vaginal hormones
Local vaginal hormones are the most effective treatment for GSM and should be the starting point for most women. They work by restoring hormones directly to the tissue that needs them, with minimal systemic absorption, which is precisely what makes them so well-tolerated and broadly safe.
Vaginal estrogen is available in several forms:
Cream applied directly to the vaginal tissue
Tablets or suppositories inserted into the vagina
The vaginal estrogen ring (Estring), inserted every 90 days for continuous low-dose delivery
Intrarosa (prasterone/DHEA) is a vaginal insert that delivers DHEA directly to vaginal tissue, where it is converted locally into both estrogen and testosterone. It works through a different mechanism than vaginal estrogen and is an excellent option for women who prefer it or who want the added benefit of local androgen activity. Many women and clinicians find it particularly effective for both tissue health and sexual symptoms.
Vaginal hormones are safe for almost all women, including women with a history of breast cancer and those on aromatase inhibitors. Systemic absorption from local vaginal hormones is minimal and does not meaningfully raise systemic estrogen levels. The only population in which we exercise specific caution is women with a history of uterine sarcoma. The long-standing reluctance to prescribe vaginal hormones to women with a breast cancer history has caused significant unnecessary suffering and is not supported by the current evidence.
It is also worth knowing that systemic hormone therapy, while beneficial for many menopausal symptoms, often does not adequately treat GSM on its own. Estrogen delivered systemically does not reliably reach high enough concentrations in vaginal and bladder tissue to reverse the local changes of GSM. Many women on systemic MHT/HRT still benefit from adding local vaginal hormones.
Vaginal moisturizers and lubricants
Non-hormonal vaginal moisturizers and lubricants are useful adjuncts but are not a substitute for vaginal hormones. Moisturizers, used regularly two to three times per week, help maintain vaginal moisture between hormone doses and can improve comfort on an ongoing basis. Lubricants are used specifically during sexual activity to reduce friction and improve comfort.
These products have a genuine role, particularly for managing dryness between hormone applications and for use during sex. But they do not reverse the underlying tissue changes of GSM the way vaginal hormones do, and they should not be recommended as a first step before hormones or withheld until a patient has tried them. For women with moderate to severe symptoms, moisturizers and lubricants alone will not be sufficient.
Water-based, silicone-based, and oil-based lubricants are all options. For perimenopausal and postmenopausal women in particular, silicone-based and oil-based lubricants tend to work better because they last longer and don't require reapplication as frequently as water-based products, which matters when vaginal dryness is more significant. One practical note: oil-based lubricants can degrade latex condoms, so they are not appropriate for women using latex contraception. Products containing glycerin, fragrances, or warming agents can cause irritation and are best avoided regardless of lubricant type.
Ospemifene
Ospemifene (Osphena) is an oral non-hormonal medication approved specifically for moderate to severe dyspareunia due to GSM. It is a selective estrogen receptor modulator (SERM) that acts like estrogen on vaginal tissue without being estrogen itself. While it is non-hormonal, it does interact with estrogen receptors, and its use is currently advised against for women with a history of estrogen-dependent cancers. It is a reasonable option for women who strongly prefer this route, though local vaginal hormones remain more directly effective for most women. Unlike local vaginal therapies, ospemifene does carry a potential increased risk of blood clots, which is an important consideration when weighing treatment options.
A note on laser and energy-based treatments
Fractional CO2 laser and radiofrequency devices are sometimes marketed for GSM, and are particularly heavily promoted to women with a history of breast cancer, often at a cost of thousands of dollars per treatment course. The evidence for these treatments is not robust enough to support their widespread use, and they are not endorsed as standard care by TMS or other major menopause organizations.
This matters because many of the women these treatments are marketed to, particularly breast cancer survivors, could safely use low-dose vaginal hormones at a fraction of the cost. Directing women toward expensive unproven treatments when safe and effective options exist is not in their best interest.
Starting treatment sooner rather than later
One of the most important things to know about GSM is that treatment is more effective when started earlier. Vaginal tissue that has been estrogen-deprived for years takes longer to respond to treatment and may not fully recover. Women who address symptoms promptly tend to have better outcomes than those who wait until symptoms are severe.
If you've been experiencing any of the symptoms described above, even if they seem mild, it's worth having a conversation with a knowledgeable clinician.
How Glow Health can help
At Glow Health, vaginal and sexual health is central to what we do. We understand that these symptoms affect far more than physical comfort, and we approach GSM as part of the full picture of a woman's health, wellbeing, and quality of life. We offer individualized treatment plans that take into account your health history, your preferences, and your goals.
You don't have to quietly manage discomfort that is both common and treatable. We'd love to help.
Keywords: vaginal dryness menopause, vaginal dryness treatment, genitourinary syndrome of menopause, GSM menopause, vaginal atrophy, painful sex menopause, vaginal estrogen, intrarosa, menopause vaginal symptoms, bladder symptoms menopause
This post is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare clinician for personalized guidance.
